213 related articles for article (PubMed ID: 27925213)
21. Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.
Shetzer Y; Napchan Y; Kaufman T; Molchadsky A; Tal P; Goldfinger N; Rotter V
Int J Cancer; 2017 Mar; 140(6):1364-1369. PubMed ID: 28008605
[TBL] [Abstract][Full Text] [Related]
22. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
[TBL] [Abstract][Full Text] [Related]
23. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice.
McDonnell TJ; Montes de Oca Luna R; Cho S; Amelse LL; Chavez-Reyes A; Lozano G
J Pathol; 1999 Jul; 188(3):322-8. PubMed ID: 10419603
[TBL] [Abstract][Full Text] [Related]
24. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
Toledo F; Wahl GM
Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
[TBL] [Abstract][Full Text] [Related]
25. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
26. Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma.
Wang Z; Zheng Y; Park HJ; Li J; Carr JR; Chen YJ; Kiefer MM; Kopanja D; Bagchi S; Tyner AL; Raychaudhuri P
Mol Cancer Ther; 2013 May; 12(5):759-67. PubMed ID: 23427295
[TBL] [Abstract][Full Text] [Related]
27. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
28. Gain of function in the mouse model of a recurrent mutation p53
Zhao L; Wang B; Zhao X; Wu X; Zhang Q; Wei C; Shi M; Li Y; Tang W; Zhang J; Yang J; Singh SK; Jia S; Luo Y
Mol Carcinog; 2018 Feb; 57(2):147-158. PubMed ID: 28949402
[TBL] [Abstract][Full Text] [Related]
29. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
[TBL] [Abstract][Full Text] [Related]
30. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
31. MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers.
Liu J; Yang J; Pan Q; Wang X; Wang X; Chen H; Zheng X; Huang Q
Eur J Med Res; 2024 Jan; 29(1):79. PubMed ID: 38281029
[TBL] [Abstract][Full Text] [Related]
32. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
33. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
34. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
[TBL] [Abstract][Full Text] [Related]
35. Tumorigenesis promotes Mdm4-S overexpression.
Pant V; Larsson CA; Aryal N; Xiong S; You MJ; Quintas-Cardama A; Lozano G
Oncotarget; 2017 Apr; 8(16):25837-25847. PubMed ID: 28460439
[TBL] [Abstract][Full Text] [Related]
36. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
[TBL] [Abstract][Full Text] [Related]
37. Synergistic regulation of p53 by Mdm2 and Mdm4 is critical in cardiac endocardial cushion morphogenesis during heart development.
Zhang Q; He X; Chen L; Zhang C; Gao X; Yang Z; Liu G
J Pathol; 2012 Nov; 228(3):416-28. PubMed ID: 22821713
[TBL] [Abstract][Full Text] [Related]
38. Lysine-specific demethylase 1 accelerates oncogenesis in p53 heterozygous mice via transcriptional repression of the residual Trp53 allele.
Wada T; Kikuchi J; Koyama D; Honda H; Furukawa Y
Leuk Res; 2019 Jul; 82():29-32. PubMed ID: 31152920
[No Abstract] [Full Text] [Related]
39. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
40. Loss of oocytes due to conditional ablation of Murine double minute 2 (Mdm2) gene is p53-dependent and results in female sterility.
Livera G; Uzbekov R; Jarrier P; Fouchécourt S; Duquenne C; Parent AS; Marine JC; Monget P
FEBS Lett; 2016 Aug; 590(16):2566-74. PubMed ID: 27364741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
